Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277185 | 0.86 | TSHR (0.50) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL276357 | 0.86 | MAPT (0.42) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL28045016 | 0.83 | ALDH1A1 (0.42) | MAPTTDP1TSHRALDH1A1CYP4A11 | |
| SCHEMBL4486192 | 0.82 | TAAR1 (0.52) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL28827835 | 0.82 | MAPT (0.47) | MAPTTDP1ALDH1A1RAB9A | |
| SCHEMBL14042112 | 0.82 | TAAR1 (0.52) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL4484678 | 0.82 | TAAR1 (0.52) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL31376526 | 0.82 | CA1 (0.52) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL867166 | 0.82 | CA1 (0.52) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL14331342 | 0.82 | MAPT (0.45) | MAPTCA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | WENZHOU UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | WENZHOU UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | WENZHOU UNIVERSITY (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | WENZHOU UNIVERSITY (CN) | 2020-06-18 | — | — | US | disclosed |
| CN-109734600-A | A kind of synthetic method of chiral beta carboxylic acid ester type compound | 温州大学 | 2019-05-10 | — | — | CN | disclosed |
| EP-1976511-A2 | FLUORINATED ARYLAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1973405-A2 | HYDROXYALKYLARYLAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007087130-A2 | HYDROXYALKYLARYLAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087129-A2 | FLUORINATED ARYLAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | HSD11B1, HACL2, HAAO | MAPT 4125/4885CA1 1736/4885CA2 1061/4885 |
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | HSD11B1, HACL2, HAAO | MAPT 4125/4885CA1 1736/4885CA2 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.